

Date: October 3, 2022

To,

Dear Sir/Madam,

<u>Subject: Press Release- Appointment of Mr. Rajeev Kumar Jain as Chief Executive Officer & Key</u> <u>Managerial Personnel</u>

Pursuant to the relevant provisions of the SEBI Listing Regulations, we are enclosing herewith Press Release for Appointment of Mr. Rajeev Kumar Jain as Chief Executive Officer & Key Managerial Personnel w.e.f. October 3, 2022.

Request you to kindly take the same on record.

Thanking you,

For Supriya Lifescience Limited

Shweta Singh Company Secretary & Compliance Officer Membership No.: A44973



Supriya Lifescience Limited Announces Mr. Rajeev Kumar Jain as Chief Executive Officer & Key Managerial Personnel

Investor Release (3rd October 2022): Supriya Lifescience Ltd. a cGMP compliant company having a well established presence in API Manufacturing with focus in products of various therapeutic segments like – Anti-Histamine, Anti-Allergics, Vitamins, Anaesthetics, Anti-Asthmatics etc. has announced appointment of Mr. Rajeev Kumar Jain as Chief Executive Officer & Key Managerial Personnel w.e.f. October 3, 2022.

Mr. Rajeev Kumar Jain has over 35+ years of rich functional experience in the manufacturing domain of Bulk Drugs, Intermediate and API with a "Safety First, Quality Must and EBIDTA Growth" mindset.

Mr Jain is a Master of Business Administration (Marketing) from Jivaji University, Gwalior and B Sc (PCB) with distinction. Additionally, he has taken part in business seminars and workshops on corporate transformation in China, Germany, and the Netherlands.

He is very skilled and experienced in managing regulations and guidelines, such as those from the USFDA, KFDA, EMA, ANVISA, CDSCO, ISO, PMDA, and IDL CHINA.

During his long span of career he has received various recognitions for his efforts in executing manufacturing excellence and performing due diligence on API units in order to acquire them and turn them into profit centres.

Throughout his career, he has maintained an impeccable record with reputable companies like Morepen Labs Ltd., Ind Swift Labs, Arch Pharma, Trident Group, Max India (DSM), etc.

He has strategic leadership attributes with a global mindset and has demonstrated lead for cross functional teams with end-to-end solutions & managing optimal utilization of Men, Machine & Material.

Rajiv is the right leader for Supriya Lifescience limited," said **Dr. Satish Wagh**, Chairman & Managing Director. Rajiv's extensive pharma background and shopfloor skills should help Supriya strengthen manufacturing excellence, develop strategic alliances and expand our international sales presence. We believe his strong leadership experience will help take Supriya to the next level of growth."

"I am very excited to be joining the Supriya team," said **Rajiv Kumar Jain**. "I believe Supriya has a great business model and talented management team that uniquely positions it to capitalize on the changing Pharmaceutical environment. As the industry evolves, I believe Supriya is in a position to reach newer heights with backward integration, focus on R&D, increasing capacity, and capitalizing on CMO/CDMO potential. Our endeavor would be to achieve healthy revenue growth with healthy margins and upgrade to the evolving GMP and EHS standards"



About Supriya Lifescience Limited

Established in the year 1987, Supriya Lifescience Ltd. is a global leading manufacturer of Active pharmaceutical Ingredients. The company was founded by Dr. Satish Wagh, a first-generation entrepreneur and technocrat. Armed with technical knowledge, business acumen and an extensive experience of more than 35 years in the pharmaceutical industry, he has been instrumental for what Supriya Lifescience is today. Company is leader in Therapeutic Segments like Anti-Histamines, Anti-Allergics, Anti-Asthmatics, Anesthetics & Vitamins. SupriyaLifescience has State-of-the-art manufacturing facility is certified by USFDA, EDQM, EUGMP, NMPA & Health Canada. Facility is located in Khed, District Ratnagiri and headquartered in Mumbai, India.

Safe Harbor

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

